Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomas

References

• MelmedSMedical progress: acromegalyN Engl J Med2006355242558257317167139
   PubMed Web of Science ®Google Scholar
• RaappanaAKoivukangasJEbelingTPirilaTIncidence of pituitary adenomas in Northern Finland in 1992–2007J Clin Endocrinol Metab20109594268427520534753
   PubMed Web of Science ®Google Scholar
• EugsterEAPescovitzOGigantismJ Clin Endocrinol Metab199984124379438410599691
   PubMed Web of Science ®Google Scholar
• EtxabeJGaztambideSLatorrePVazquezJAAcromegaly: an epidemiological studyJ Endocrinol Invest19931631811878514973
   PubMed Web of Science ®Google Scholar
• GelberSJHeffezDSDonohouePAPituitary gigantism caused by growth hormone excess from infancyJ Pediatr199212069319341593354
   PubMed Web of Science ®Google Scholar
• ColaoAPivonelloRDi SommaCTauchmanovàLSavastanoSLombardiGGrowth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcomeClin Endocrinol (Oxf)200766571472217388794
   PubMed Web of Science ®Google Scholar
• ShimatsuATeramotoAHizukaNKitaiKRamisJChiharaKEfficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantismEndocr J201360565166323337477
   PubMed Web of Science ®Google Scholar
• Näntö-SalonenKKoskinenPSonninenPToppariJSuppression of GH secretion in pituitary gigantism by continuous subcutaneous octreotide infusion in a pubertal boyActa Paediatr1999881293310090543
   PubMed Web of Science ®Google Scholar
• MelmedSAcromegaly pathogenesis and treatmentJ Clin Invest2009119113189320219884662
   PubMed Web of Science ®Google Scholar
• AndersonDFaberPMarcovitzSHardyJLorenzettiDPituitary tumors and the ophthalmologistOphthalmology19839011126512706664664
   PubMed Web of Science ®Google Scholar
• ArafahBMPruntyDYbarraJHlavinMLSelmanWRThe dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomasJ Clin Endocrinol Metab20008551789179310843153
   PubMed Web of Science ®Google Scholar
• ColaoAFeroneDMarzulloPLombardiGSystemic complications of acromegaly: epidemiology, pathogenesis, and managementEndocr Rev200425110215214769829
   PubMed Web of Science ®Google Scholar
• HoldawayIMRajasooryaRCGambleGDFactors influencing mortality in acromegalyJ Clin Endocrinol Metab200489266767414764779
   PubMed Web of Science ®Google Scholar
• MelmedSColaoABarkanAAcromegaly Consensus GroupGuidelines for acromegaly management: an updateJ Clin Endocrinol Metab20099451509151719208732
   PubMed Web of Science ®Google Scholar
• AlexopoulouOBexMAbsRT’SjoenGVelkeniersBMaiterDDivergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegalyJ Clin Endocrinol Metab20089341324133018230660
   PubMed Web of Science ®Google Scholar
• HoldawayIMBollandMJGambleGDA meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegalyEur J Endocrinol20081592899518524797
   PubMed Web of Science ®Google Scholar
• ColaoAAttanasioRPivonelloRPartial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegalyJ Clin Endocrinol Metab2006911859216263832
   PubMed Web of Science ®Google Scholar
• PetrossiansPBorges-MartinsLEspinozaCGross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogsEur J Endocrinol20051521616615762188
   PubMed Web of Science ®Google Scholar
• JenkinsPJBatesPCarsonMNStewartPMWassJConventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegalyJ Clin Endocrinol Metab20069141239124516403824
   PubMed Web of Science ®Google Scholar
• MaizaJCVezzosiDMattaMLong-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatosta-tin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTaClin Endocrinol (Oxf)200767228228917524029
   PubMed Web of Science ®Google Scholar
• LucasTAstorgaRSpanish-Portuguese Multicentre Autogel Study Group on AcromegalyEfficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trialClin Endocrinol (Oxf)200665332032616918950
   PubMed Web of Science ®Google Scholar
• CaronPBeckersACullenDREfficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegalyJ Clin Endocrinol Metab20028719910411788630
   PubMed Web of Science ®Google Scholar
• CaronPBexMCullenDRGroup for Lanreotide Autogel Long-Term Study on AcromegalyOne-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide AutogelClin Endocrinol (Oxf)200460673474015163338
   PubMed Web of Science ®Google Scholar
• GuttBBidlingmaierMKretschmarKDieterleCSteffinBSchopohlJFour-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel)Exp Clin Endocrinol Diabetes2005113313914415789272
   PubMed Web of Science ®Google Scholar
• CaronPMorange-RamosICogneMJaquetPThree year follow-up of acromegalic patients treated with intramuscular slow-release lanreotideJ Clin Endocrinol Metab199782118228989225
   PubMed Web of Science ®Google Scholar
• MurrayRDMelmedSA critical analysis of clinically available somatostatin analog formulations for therapy of acromegalyJ Clin Endocrinol Metab20089382957296818477663
   PubMed Web of Science ®Google Scholar
• AndriesMGlintborgDKvistborgAHagenCAndersenMA 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-I in patients with acromegalyClin Endocrinol (Oxf)200868347348017941902
   PubMed Web of Science ®Google Scholar
• van der LelyAJBillerBMBrueTLong-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDYJ Clin Endocrinol Metab20129751589159722362824
   PubMed Web of Science ®Google Scholar
• FeenstraJde HerderWWten HaveSCombined therapy with somatostatin analogues and weekly pegvisomant in active acromegalyLancet200536594711644164615885297
   PubMed Web of Science ®Google Scholar
• NeggersSJde HerderWWJanssenJAFeeldersRAvan der LelyAJCombined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patientsEur J Endocrinol2009160452953319141604
   PubMed Web of Science ®Google Scholar
• AbsRVerhelstJMaiterDCabergoline in the treatment of acro-megaly: a study in 64 patientsJ Clin Endocrinol Metab19988323743789467544
   PubMed Web of Science ®Google Scholar
• SandretLMaisonPChansonPPlace of cabergoline in acromegaly: a meta-analysisJ Clin Endocrinol Metab20119651327133521325455
   PubMed Web of Science ®Google Scholar
• ColaoAAuriemmaRSLombardiGPivonelloRResistance to soma-tostatin analogs in acromegalyEndocr Rev201132224727121123741
   PubMed Web of Science ®Google Scholar
• NewmanCBMelmedSSnyderPJSafety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients – a clinical research center studyJ Clin Endocrinol Metab1995809276827757673422
   PubMed Web of Science ®Google Scholar
• BevanJSAtkinSLAtkinsonABPrimary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor sizeJ Clin Endocrinol Metab200287104554456312364434
   PubMed Web of Science ®Google Scholar
• ReubiJCLandoltAMThe growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor statusJ Clin Endocrinol Metab19896848448502537844
   PubMed Web of Science ®Google Scholar
• ColaoAAuriemmaRSReboraASignificant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegalyClin Endocrinol (Oxf)200971223724519094074
   PubMed Web of Science ®Google Scholar
• HoflandLJLambertsSWThe pathophysiological consequences of somatostatin receptor internalization and resistanceEndocr Rev2003241284712588807
   PubMed Web of Science ®Google Scholar
• BertheratJChansonPDewaillyDSomatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomasJ Clin Endocrinol Metab1993776157715837903312
   PubMed Web of Science ®Google Scholar
• ColaoAPivonelloRCappabiancaPEffect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegalyClin Endocrinol (Oxf)200563334234916117824
   PubMed Web of Science ®Google Scholar
• ColaoAPivonelloRSpinelliLA retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patientsJ Endocrinol Invest200730649750617646725
   PubMed Web of Science ®Google Scholar
• ColaoAFeroneDLastoriaSPrediction of efficacy of octreotide therapy in patients with acromegalyJ Clin Endocrinol Metab1996816235623628964877
   PubMed Web of Science ®Google Scholar
• KaravitakiNBotusanIRadianSCoculescuMTurnerHEWassJAThe value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegalyClin Endocrinol (Oxf)200562328228815730408
   PubMed Web of Science ®Google Scholar
• LambertsSWUitterlindenPSchuijffPCKlijnJGTherapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical ‘cure’Clin Endocrinol (Oxf)19882944114203251673
   PubMed Web of Science ®Google Scholar
• FredaPUKatznelsonLvan der LelyAJReyesCMZhaoSHRabinowitzDLong-acting somatostatin analog therapy of acromegaly: a meta-analysisJ Clin Endocrinol Metab20059084465447315886238
   PubMed Web of Science ®Google Scholar
• PlöckingerUBäderMHopfenmüllerWSaegerWQuabbeHJResults of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to octreotide therapy and do not correlate with tumor histologyEur J Endocrinol199713643693769150695
   PubMed Web of Science ®Google Scholar
• LegoviniPDe MenisEBilleciDContiBZoliPConteN111 Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patientsJ Endocrinol Invest19972074244289309542
   PubMed Web of Science ®Google Scholar
• GoergesRBockischACordesUCorrelation between pituitary In-111-pentetreotide uptake and growth hormone (GH) response to octreotide in acromegalyEur J Endocrinol199626Suppl 1A55
   Google Scholar
• CendrosJMPeraireCTrocónizIFObachRPharmacokinetics and population pharmacodynamic analysis of lanreotide AutogelMetabolism200554101276128116154424
   PubMed Web of Science ®Google Scholar
• BronsteinMMusolinoNJalladRPharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 daysClin Endocrinol (Oxf)200563551451916268802
   PubMed Web of Science ®Google Scholar
• AstrucBMarbachPBouterfaHLong-acting octreotide and prolonged-release lanreotide formulations have different pharmacoki-netic profilesJ Clin Pharmacol200545783684415951474
   PubMed Web of Science ®Google Scholar
• CroxtallJDScottLJLanreotide Autogel: a review of its use in the management of acromegalyDrugs200868571172318370450
   PubMed Web of Science ®Google Scholar
• CaronPSomatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patientsAnn Endocrinol (Paris)2002632 Pt 32S192S24 French12037499
   PubMed Web of Science ®Google Scholar
• AnnamalaiAKWebbAKandasamyNA comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapyJ Clin Endocrinol Metab20139831040105023393175
   PubMed Web of Science ®Google Scholar
• Ben-ShlomoAMelmedSClinical review 154: The role of pharma-cotherapy in perioperative management of patients with acromegalyJ Clin Endocrinol Metab200388396396812629068
   PubMed Web of Science ®Google Scholar
• SeidmanPAKofkeWAPolicareRYoungMAnaesthetic complications of acromegalyBr J Anaesth200084217918210743450
   PubMed Web of Science ®Google Scholar
• ColaoAFeroneDCappabiancaPEffect of octreotide pretreatment on surgical outcome in acromegalyJ Clin Endocrinol Metab19978210330833149329359
   PubMed Web of Science ®Google Scholar
• ManelliFDesenzaniPBoniECardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophyPituitary19992320521011081155
   PubMedGoogle Scholar
• HoogwerfBJPostoperative management of the diabetic patientMed Clin North Am20018551213122811565495
   PubMed Web of Science ®Google Scholar
• CoutureEBongardVMaizaJCBennetACaronPGlucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotidePituitary201215451852522058008
   PubMed Web of Science ®Google Scholar
• SteffinBGuttBBidlingmaierMDieterleCOltmannFSchopohlJEffects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegalyEur J Endocrinol20061551737816793952
   PubMed Web of Science ®Google Scholar
• Pita-GutierrezFPertega-DiazSPita-FernandezSPlace of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysisPLoS One20138e6152323634209
   PubMed Web of Science ®Google Scholar
• AbeTLüdeckeDKEffects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centreEur J Endocrinol2001145213714511454508
   PubMed Web of Science ®Google Scholar
• ShenMShouXWangYEffect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized studyEndocr J201057121035104421099129
   PubMed Web of Science ®Google Scholar
• ColaoAThe importance of presurgical somatostatin analogue therapy in acromegalyEndokrynol Pol200758435636018058729
   PubMedGoogle Scholar
• LosaMMortiniPUrbazLRibottoPCastrignanóTGiovanelliMPresurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication ratesJ Neurosurg2006104689990616776333
   PubMed Web of Science ®Google Scholar
• OshinoSSaitohYKasayamaSShort-term preoperative octreotide treatment of GH-secreting pituitary adenoma: Predictors of tumor shrinkageEndocr J200653112513216543682
   PubMed Web of Science ®Google Scholar
• LudeckeDKAbeTTranssphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operationsNeuroendocrinology2006833–423023917047388
   PubMed Web of Science ®Google Scholar
• YinJSuCBXuZQEffect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgeryChin Med Sci J2005201232615844307
   PubMedGoogle Scholar
• PlöckingerUQuabbeHJPresurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control studyActa Neurochir (Wien)2005147548549315806331
   PubMed Web of Science ®Google Scholar
• LucasTAstorgaRCataláMSpanish Multicentre Lanreotide Study Group on AcromegalyPreoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkageClin Endocrinol (Oxf)200358447148112641631
   PubMed Web of Science ®Google Scholar
• StevenaertABeckersAPresurgical Octreotide: treatment in acromegalyMetabolism1996458 Suppl 172748769388
   PubMed Web of Science ®Google Scholar
• DePReesDADaviesNTranssphenoidal surgery for acromegaly in wales: results based on stringent criteria of remissionJ Clin Endocrinol Metab20038883567357212915637
   PubMed Web of Science ®Google Scholar
• NomikosPBuchfelderMFahlbuschRThe outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’Eur J Endocrinol2005152337938715757854
   PubMed Web of Science ®Google Scholar
• KaltsasGAIsidoriAMFlorakisDPredictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activityJ Clin Endocrinol Metab20018641645165211297598
   PubMed Web of Science ®Google Scholar
• ShimonICohenZRRamZHadaniMTranssphenoidal surgery for acromegaly: endocrinological follow-up of 98 patientsNeurosurgery200148612391243 discussion 1244–124511383725
   PubMed Web of Science ®Google Scholar
• BeauregardCTruongUHardyJSerriOLong-term outcome and mortality after transsphenoidal adenomectomy for acromegalyClin Endocrinol (Oxf)2003581869112519417
   PubMed Web of Science ®Google Scholar
• MaoZGZhuYHTangHLPreoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trialEur J Endocrinol2010162466166620061334
   PubMed Web of Science ®Google Scholar
• GiustinaABronsteinMDCasanuevaFFCurrent management practices for acromegaly: an international surveyPituitary201114212513321063787
   PubMed Web of Science ®Google Scholar
• GrassoLFPivonelloRColaoASomatostatin analogs as a first-line treatment in acromegaly: when is it appropriate?Curr Opin Endocrinol Diabetes Obes201219428829422627686
   PubMed Web of Science ®Google Scholar
• NeggersSJvan AkenMOde HerderWWQuality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomantJ Clin Endocrinol Metab200893103853385918647806
   PubMed Web of Science ®Google Scholar
• FendriSKaracaPTievEBuchfelderMLalauJControl of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patientAnn Endocrinol (Paris)2013741495223337021
   PubMed Web of Science ®Google Scholar
• NeggersSJde HerderWWFeeldersRAvan der LelyAJConversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patientsPituitary201114325325821221818
   PubMed Web of Science ®Google Scholar
• MadsenMPoulsenPLOrskovHMøllerNJørgensenJOCotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patientsJ Clin Endocrinol Metab20119682405241321632808
   PubMed Web of Science ®Google Scholar
• van der LelyABernabeuICapJCoadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs aloneEur J Endocrinol2011164332533321148630
   PubMed Web of Science ®Google Scholar
• Sowiń skiJSawickaNPiatekKZybekARuchalaMPharmacoeconomic aspects of the treatment of pituitary gland tumoursContemp Oncol (Pozn)201317213714323788980
   PubMed Web of Science ®Google Scholar
• LewisIBauerWAlbertRA novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potentialJ Med Chem200346122334234412773038
   PubMed Web of Science ®Google Scholar
• PetersennSFarrallAJBlockCLong-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension studyPituitary Epub3262013
   Web of Science ®Google Scholar
• ColaoAPetersennSNewell-PriceJA 12-month phase 3 study of pasireotide in Cushing’s diseaseN Engl J Med20123661091492422397653
   PubMed Web of Science ®Google Scholar
• HoflandLJvan der HoekJvan KoetsveldPMThe novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitroJ Clin Endocrinol Metab20048941577158515070915
   PubMed Web of Science ®Google Scholar
• MurrayRDKimKRenSGThe novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretionJ Clin Endocrinol Metab20048963027303215181094
   PubMed Web of Science ®Google Scholar
• GruszkaACullerMDMelmedSSomatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitroMol Cell Endocrinol20123621–210410922705877
   PubMed Web of Science ®Google Scholar
• CunyTMohamedAGraillonTSomatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretionMol Cell Endocrinol2012355110611322348806
   PubMed Web of Science ®Google Scholar
• PlöckingerUHoffmannUGeeseMDG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumoursEur J Endocrinol2012166222323422065857
   PubMed Web of Science ®Google Scholar
• LuPWSilinkMJohnstonICowellCTJimenezMPituitary gigantismArch Dis Child1992678
   Web of Science ®Google Scholar